Tumor Biology

, Volume 33, Issue 6, pp 2079–2089 | Cite as

Cytochrome P450 1A1 Ile462Val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls

Research Article

Abstract

Cytochrome P450 (CYP) 1A1 Ile462Val (exon7) polymorphism has been suggested to be a risk factor for several cancers. Published data on its association with oral cancer risk have generated conflicting results. Our previous meta-analysis containing data from prior to Jan 2008 regarding this issue failed to find a significant association between CYP1A1 Ile462Val variation and oral cancer susceptibility. An updated meta-analysis with eligible studies for the period up to May 2012 was conducted. Separate analyses on ethnicity and source of controls were also performed. A total of 13 case–control studies comprising 1,515 cases and 2,233 controls were lastly selected for analysis. Compared with the previous meta-analysis, the overall data also failed to indicate a significant association of CYP1A1 Ile462Val polymorphism with oral cancer risk (Val/Val vs. Ile/Ile—OR = 1.46; 95 % CI = 0.96–2.24; dominant model—OR = 1.01; 95 % CI = 0.81–1.25; and recessive model—OR = 1.46; 95 % CI = 0.96–2.23). However, in the subgroup analysis by ethnicity, increased cancer risk was observed among Asians under the additive and recessive models (Val/Val vs. Ile/Ile—OR = 1.74; 95 % CI = 1.04–2.90 and recessive model—OR = 1.73; 95 % CI = 1.04–2.87), inconsistent with the previous meta-analysis. Collectively, the data of the present study suggest that CYP1A1 variant Val/Val alleles might modify the susceptibility to oral cancer among Asians. Further well-designed investigations with large sample sizes are required to confirm this conclusion.

Keywords

CYP1A1 Ile462Val Mouth neoplasm Susceptibility Meta-analysis Polymorphism 

Notes

Acknowledgments

This work was supported by Initial Fund for Doctors of Guiyang Medical College (2009-14) and China Postdoctoral Science Foundation (20100471772).

Conflicts of interest

None

References

  1. 1.
    Zygogianni AG, Kyrgias G, Karakitsos P, Psyrri A, Kouvaris J, Kelekis N, Kouloulias V. Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 2011;3:2.PubMedCrossRefGoogle Scholar
  2. 2.
    Reichart PA, Nguyen XH. Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med. 2008;37:511–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhuo W, Wang Y, Zhuo X, Zhu Y, Wang W, Zhu B, Li D, Chen Z. CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. Cancer Invest. 2009;27:86–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhou C, Zhou Y, Li J, Zhang Y, Jiang L, Zeng X, Feng X, Wang Z. The ARG194TRP polymorphism in the X-ray repair cross-complementing group 1 gene as a potential risk factor of oral cancer: a meta-analysis. Tohoku J Exp Med. 2009;219:43–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Niu Y, Hu Y, Wu M, Jiang F, Shen M, Tang C, Chen N. CYP2E1 Rsa I/Pst I polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:607–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhuo XL, Li Q, Zhou Y, Cai L, Xiang ZL, Yuan W, Zhang XY. Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res. 2009;40:625–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Vineis P. Individual susceptibility to carcinogens. Oncogene. 2004;23:6477–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Duarte EC, Ribeiro DC, Gomez MV, Ramos-Jorge ML, Gomez RS. Genetic polymorphisms of carcinogen metabolizing enzymes are associated with oral leukoplakia development and P53 overexpression. Anticancer Res. 2008;28:1101–6.PubMedGoogle Scholar
  9. 9.
    Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res. 1998;400:201–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Lukowsky A, Sterry W, Schneider-Burrus S. Prevalence of the MspI and Ile462val SNPs of cytochrome P-450 1a1 in Hidradenitis suppurativa. Exp Dermatol. 2010;19:541–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89–295.PubMedCrossRefGoogle Scholar
  12. 12.
    Rojas M, Cascorbi I, Alexandrov K, Kriek E, Auburtin G, Mayer L, Kopp-Schneider A, Roots I, Bartsch H. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis. 2000;21:35–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Nair U, Bartsch H. Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci Publ. 2001;154:271–90.PubMedGoogle Scholar
  19. 19.
    Varela-Lema L, Taioli E, Ruano-Ravina A, Barros-Dios JM, Anantharaman D, Benhamou S, Boccia S, Bhisey RA, Cadoni G, Capoluongo E, Chen CJ, Foulkes W, Goloni-Bertollo EM, Hatagima A, Hayes RB, Katoh T, Koifman S, Lazarus P, Manni JJ, Mahimkar M, Morita S, Park J, Park KK, Pavarino Bertelli EC, de Souza Fonseca Ribeiro EM, Roy B, Spitz MR, Strange RC, Wei Q, Ragin CC. Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med: Off J Am Coll Med Genet. 2008;10:369–84.Google Scholar
  20. 20.
    Bartsch H, Rojas M, Nair U, Nair J, Alexandrov K. Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev. 1999;23:445–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Sikdar N, Mahmud SA, Paul RR, Roy B. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 2003;195:33–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Lazarus P, Sheikh SN, Ren Q, Schantz SP, Stern JC, Richie Jr JP, Park JY. P53, but not P16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis. 1998;19:509–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW, Hand P, Gilford J, Farrell WE, Hoban P, Fryer AA, Strange RC. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics. 1998;8:433–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF, Hand P, Fryer AA, Strange RC. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998;8:91–100.PubMedGoogle Scholar
  25. 25.
    Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:185–91.PubMedGoogle Scholar
  26. 26.
    Varela-Lema L, Ruano-Ravina A, Juiz Crespo MA, Kelsey KT, Loidi L, Barros-Dios JM. CYP1A1, mEH, and GSTM1 polymophisms and risk of oral and pharyngeal cancer: a Spanish case–control study. J Oncol. 2008;2008:741310.PubMedCrossRefGoogle Scholar
  27. 27.
    Canova C, Richiardi L, Merletti F, Pentenero M, Gervasio C, Tanturri G, Garzino-Demo P, Pecorari G, Talamini R, Barzan L, Sulfaro S, Franchini G, Muzzolini C, Bordin S, Pugliese GN, Macri E, Simonato L. Alcohol, tobacco and genetic susceptibility in relation to cancers of the upper aerodigestive tract in northern Italy. Tumori. 2010;96:1–10.PubMedGoogle Scholar
  28. 28.
    Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK, Chi LY, Liu TY. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med. 2002;31:505–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291–306.PubMedCrossRefGoogle Scholar
  30. 30.
    Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, Pike V, Richie Jr JP, Lazarus P. CYP1A1 and Gstm1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev. 1997;6:791–7.PubMedGoogle Scholar
  31. 31.
    Matthias C, Bockmuhl U, Jahnke V, Harries LW, Wolf CR, Jones PW, Alldersea J, Worrall SF, Hand P, Fryer AA, Strange RC. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics. 1998;8:1–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H, Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer. 1999;80:685–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer. 1999;83:606–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. 2000;36:267–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002;38:486–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity. Oral Dis. 2003;9:62–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Xie H, Hou L, Shields PG, Winn DM, Gridley G, Bravo-Otero E, Diehl SR, Bowman ED, Brown LM, Hayes RB. Metabolic polymorphisms, smoking, and oral cancer in Puerto Rico. Oncol Res. 2004;14:315–20.PubMedGoogle Scholar
  38. 38.
    Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, Mitsudo K, Ueda M, Tajima K, Ishizaki K. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med. 2006;35:11–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P, Hatagima A. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case–control study in Rio de Janeiro. Oral Oncol. 2006;42:632–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Leichsenring A, Losi-Guembarovski R, Maciel ME, Losi-Guembarovski A, Oliveira BW, Ramos G, Cavalcanti TC, Bicalho MG, Cavalli IJ, Colus IM, Ribeiro EM. CYP1A1 and GSTP1 polymorphisms in an oral cancer case–control study. Braz J Med Biol Res. 2006;39:1569–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M. Case–control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck. 2008;30:1139–47.PubMedCrossRefGoogle Scholar
  42. 42.
    Amtha R, Ching CS, Zain R, Razak IA, Basuki B, Roeslan BO, Gautama W, Purwanto D. GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case–control study in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2009;10:21–6.PubMedGoogle Scholar
  43. 43.
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull. 1999;8:15–7.Google Scholar
  44. 44.
    Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, Chen ZT. Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res. 2009;40:169–79.PubMedCrossRefGoogle Scholar
  45. 45.
    Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:6647–54.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MSPI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res. 2011;30:99.PubMedCrossRefGoogle Scholar
  47. 47.
    Zheng Y, Wang JJ, Sun L, Li HL. Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:3533–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:459–69.PubMedCrossRefGoogle Scholar
  49. 49.
    Zhuo WL, Wang Y, Zhuo XL, Zhu B, Zhu Y, Chen ZT. Polymorphisms of CYP1A1 and GSTM1 and laryngeal cancer risk: evidence-based meta-analyses. J Cancer Res Clin Oncol. 2009;135:1081–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urol J. 2009;6:78–86.PubMedGoogle Scholar
  51. 51.
    Guo R, Guo X: Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol 2012;(in press)Google Scholar
  52. 52.
    Lee CC, Chien SH, Hung SK, Yang WZ, Su YC. Effect of individual and neighborhood socioeconomic status on oral cancer survival. Oral Oncol. 2012;48:253–61.PubMedCrossRefGoogle Scholar
  53. 53.
    Adeyemi BF, Olusanya AA, Lawoyin JO. Oral squamous cell carcinoma, socioeconomic status and history of exposure to alcohol and tobacco. J Natl Med Assoc. 2011;103:498–502.PubMedGoogle Scholar
  54. 54.
    Zhang ZJ, Hao K, Shi R, Zhao G, Jiang GX, Song Y, Xu X, Ma J. Glutathione S-transferase m1 (GSTM1) and glutathione S-transferase t1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a huge review and meta-analysis. Am J Epidemiol. 2011;173:847–57.PubMedCrossRefGoogle Scholar
  55. 55.
    Supic G, Jovic N, Kozomara R, Zeljic K, Magic Z. Interaction between the MTHFR c677t polymorphism and alcohol—impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J Dent Res. 2011;90:65–70.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Stomatology, Xinqiao HospitalThird Military Medical UniversityChongqingChina
  2. 2.Affiliated Hospital of Guiyang Medical CollegeGuiyangChina

Personalised recommendations